Time trend and risk factors for reoperation in Crohn's disease in Japan

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1081-1086

  Watanabe, Toshiaki ^a   Sasaki, Iwao ^b   Sugita, Akira ^c   Fukushima, Kohei ^b   Futami, Kitaro ^d   Hibi, Toshifumi ^e   Watanabe, Mamoru ^f  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Yokohama Municipal Hospital   (Japan)

^d Fukuoka University Chikushi Hospital   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Crohn's disease; Reoperation; Risk factor; Second surgery; Surgery; Time changes; Time trend

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CROHN DISEASE; DISEASE DURATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SURGICAL RISK; TREND STUDY;

ADOLESCENT; ADULT; CHILD; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REOPERATION; RISK FACTORS; TIME FACTORS;

EID: 84861414896     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10822     Document Type: Article

References (43)

1. Simillis C, Yamamoto T, Reese GE, et al.: A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus non-perforating Crohn's disease. Am J Gastroenterol 2008; 103(1):196-205.
2. Yamamoto T, Fazio VW, Tekkis PP: Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis Colon Rectum 2007; 50(11):1968-1986.
3. Williams JG, Wong WD, Rothenberger DA, Goldberg SM: Recurrence of Crohn's disease after resection. Br J Surg 1991; 78(1):10-19.
4. Bernell O, Lapidus A, Hellers G: Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 2000; 87(12):1697-1701.
5. Velayos FS, Sandborn WJ: Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol 2009; 104(8):2097-2099.
6. Bernell O, Lapidus A, Hellers G: Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231(1):38-45.
7. Yamamoto T: Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11(26):3971-3979.
8. Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127(3):723-729.
9. Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127(3):730-740.
10. D'Haens GR, Vermeire S, Van Assche G, et al.: Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135(4):1123-1129.
11. Blum E, Katz JA: Postoperative therapy for Crohn's disease. Inflamm Bowel Dis 2009; 15(3):463-472.
12. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al.: Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104(8):2089-2096.
13. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350(9):876-885.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317):1541-1549.
15. Vermeire S, van Assche G, Rutgeerts P: Review article: Altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25(1):3-12.
16. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126(2):402-413.
17. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128(4):862-869.
18. Regueiro M, Schraut W, Baidoo L, et al.: Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136(2):441-450.
19. Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54(2):237-241.
20. Wolters FL, Russel MG, Stockbrügger RW: Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20(5):483-496.
21. Vind I, Riis L, Jess T, et al.: Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101(6):1274-1282.
22. Jess T, Riis L, Vind I, et al.: Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13(4):481-489.
23. Takagi S, Utsunomiya K, Kuriyama S, et al.: Effectiveness of a 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment Pharmacol Ther 2006; 24(9):1333-1340.
24. Oriuchi T, Hiwatashi N, Kinouchi Y, et al.: Clinical course and long-term prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation and mortality. J Gastroenterol 2003; 38(10):942-953.
25. Yamamoto T, Umegae S, Matsumoto K: Impact of infliximab therapy after early endoscopic recurrence following ileocolic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009; 15(10):1460-1466.
26. Yao T, Matsui T, Hiwatashi N: Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000; 43(10):S85-S93.
27. Greenstein AJ, Lachman P, Sachar DB, et al.: Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988; 29(5):588-592.
28. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ: The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105(2):289-297.
29. Bewtra M, Su C, Lewis JD: Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5(5):597-601.
30. Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR: Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007; 13(12):1529-1535.
31. Bernstein CN, Nabalamba A: Hospitalization, surgery, and re-admission rates of IBD in Canada: a population-based study. Am J Gastroenterol 2006; 101(1):110-118.
32. Lapidus A, Bernell O, Hellers G, Löfberg R: Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114(6):1151-1160.
33. Herrinton LJ, Liu L, Fireman B, et al.: Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137(2):502-511.
34. Regueiro M, Schraut W, Baidoo L, et al.: Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136(2):441-450.
35. Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002; 35(2):151-166.
36. Sorrentino D, Terrosu G, Avellini C, Maiero S: Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolic Crohn disease. Arch Intern Med 2007; 167(16):1804-1807.
37. Herfarth H, Tjaden C, Lukas M, et al.: ZT-1 Study Group. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 2006; 55(10):1525-1526.
38. Domènech E, Mañosa M, Bernal I, et al.: Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis 2008; 14(4):508-513.
39. Sutherland LR, Ramcharan S, Bryant H, Fick G: Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98(5 Pt 1):1123-1128.
40. Sachar DB, Wolfson DM, Greenstein AJ, et al.: Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983; 85(4):917-921.
41. Ogata H, Hibi T: Does an elemental diet affect operation and/ or recurrence rate in Crohn's disease in Japan? J Gastroenterol 2003; 38(10):1019-1021.
42. Ikeuchi H, Kusunoki M, Yanagi H,Yamamura T, Fukuda Y, Shimoyama T: Effects of elemental diet (ED) on surgical treatment in Crohn's disease. Hepato-gastroenterol 2000; 47(32):390-392.
43. Sandborn WJ, Feagan BG: The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 2004; 127(3):990-993.